Completed PHASE3 INTERVENTIONAL 2-arm NCT03687372

Study of A-101 Topical Solution for the Treatment of Common Warts

A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts

Sponsor: Aclaris Therapeutics, Inc.

Conditions Common Wart

Interventions A-101 vehicle

Updated 7 times since 2018 Last updated: Sep 11, 2020 Started: Sep 17, 2018 Primary completion: Jun 20, 2019 Completion: Sep 6, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Common Wart and is currently completed. Aclaris Therapeutics, Inc. leads this study, which shows 7 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Oct 2020 — Jan 2021 [monthly]

Completed PHASE3
Nov 2019 — Oct 2020 [monthly]

Completed PHASE3

Status: Recruiting → Completed

▶ Show 2 earlier versions

Apr 2019 — Nov 2019 [monthly]

Recruiting PHASE3
Oct 2018 — Apr 2019 [monthly]

Recruiting PHASE3

First recorded

Sep 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aclaris Therapeutics, Inc.

Data source: Aclaris Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Aventura, United States , Broomall, United States , Charleston, United States , Chestnut Hill, United States , Fort Washington, United States , Fountain Valley, United States , Fridley, United States , Greenville, United States , Hot Springs, United States and 14 more locations